Danel (DANE) AI Stock Analysis

• Market Cap: 2.75B
• Dividend Yield: 3.01%
• Average Volume (3M): 11.82K
• Price to Earnings (P/E): 128.8
• Beta (1Y): 1.09
• Revenue Growth: 5.94%
• EPS Growth: -52.48%
• Country: IL
• Employees: 4,290
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Medical - Care Facilities
• EPS (TTM): 587.00
• Shares Outstanding: 5,915,375
• 10 Day Avg. Volume: 13,517
• 30 Day Avg. Volume: 11,824
• PEG Ratio: -0.40
• Price to Book (P/B): 5.14
• Price to Sales (P/S): 0.84
• P/FCF Ratio: 12.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: 46,200.00 ▼(-0.73% Downside)

Danel's overall stock score is primarily influenced by its strong financial performance, characterized by robust revenue growth and stable financial health. However, the stock faces significant challenges in technical analysis, with bearish momentum and overvaluation concerns due to a high P/E ratio. These factors contribute to a moderate overall score.

Positive Factors

Revenue Growth

Danel's strong revenue growth reflects its successful market penetration and increasing demand for its analytics platforms, which supports long-term business expansion.

Cash Flow Generation

The significant increase in free cash flow enhances Danel's ability to reinvest in growth opportunities and maintain financial stability, supporting its long-term strategic goals.

Stable Financial Health

Danel's stable financial health and moderate leverage provide a solid foundation for sustainable growth and resilience against economic fluctuations.

Negative Factors

Low Profit Margins

Danel's low profit margins indicate challenges in achieving operational efficiency, which could hinder its ability to maximize shareholder returns over the long term.

Operational Inefficiencies

Decreasing EBIT and EBITDA margins suggest operational inefficiencies, potentially impacting Danel's ability to scale profitably and maintain competitive advantage.

Low Return on Equity

A low return on equity may indicate that Danel is not effectively utilizing its equity base to generate profits, which could affect long-term investor confidence.

Danel Business Overview & Revenue Model

Company Description

Danel (DANE) is a technology-driven company specializing in the development and deployment of innovative software solutions for the healthcare and financial sectors. The company focuses on enhancing operational efficiencies and customer engagement through its suite of applications, which includes data analytics tools, patient management systems, and secure transaction platforms. Danel aims to leverage cutting-edge technologies to empower organizations in managing their processes more effectively and improving service delivery.

How the Company Makes Money

Danel generates revenue primarily through a subscription-based model, where clients pay for access to its software solutions on a monthly or annual basis. In addition to subscription fees, the company also earns income from consulting services, which include implementation, customization, and ongoing support for its clients. Key partnerships with healthcare providers and financial institutions further bolster Danel's revenue streams, allowing for integration of its products into existing systems and expanding its market reach. Moreover, Danel may receive additional income from licensing its technology to third parties, thereby creating multiple pathways for revenue generation.

Danel Financial Statement Overview

Summary

Danel exhibits strong revenue growth and stable financial health, but faces challenges in profitability and operational efficiency. The company maintains a solid balance sheet with moderate leverage and a strong cash flow position, which supports its growth trajectory. However, improving margins and returns on equity could enhance shareholder value.

Income Statement

Danel's income statement shows moderate growth and profitability. The TTM revenue growth rate is strong at 91.7%, indicating robust expansion. However, margins are relatively low, with a gross profit margin of 18.34% and a net profit margin of 0.83%, suggesting limited profitability. The EBIT and EBITDA margins have decreased over time, reflecting potential operational inefficiencies.

Balance Sheet

The balance sheet is stable with a manageable debt-to-equity ratio of 0.69 in the TTM period, indicating moderate leverage. The return on equity is low at 4.71%, suggesting limited returns for shareholders. The equity ratio stands at 36.89%, reflecting a solid equity base relative to total assets.

Cash Flow

Cash flow analysis reveals strong free cash flow growth of 273.4% in the TTM period, highlighting improved cash generation. The operating cash flow to net income ratio is 4.59, indicating healthy cash flow relative to earnings. However, the free cash flow to net income ratio has decreased slightly, suggesting potential challenges in converting earnings to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.84B	2.77B	2.51B	2.36B	2.29B	1.98B
Gross Profit	519.90M	510.71M	458.31M	464.44M	492.51M	410.04M
EBITDA	153.13M	223.61M	84.01M	206.17M	283.44M	216.13M
Net Income	23.42M	20.51M	-11.22M	115.79M	174.15M	127.36M
Balance Sheet
Total Assets	1.37B	1.31B	1.30B	1.27B	1.13B	1.02B
Cash, Cash Equivalents and Short-Term Investments	256.57M	251.20M	185.15M	139.98M	81.09M	141.41M
Total Debt	346.66M	363.56M	376.07M	335.48M	262.58M	193.71M
Total Liabilities	857.13M	853.41M	816.38M	758.19M	729.68M	688.47M
Stockholders Equity	504.27M	452.26M	471.44M	493.17M	364.45M	291.45M
Cash Flow
Free Cash Flow	192.03M	187.65M	156.91M	141.66M	180.19M	243.20M
Operating Cash Flow	253.19M	223.06M	206.72M	205.71M	231.64M	266.34M
Investing Cash Flow	-60.17M	-34.05M	-73.82M	-79.02M	-124.25M	-56.24M
Financing Cash Flow	-140.55M	-122.96M	-87.73M	-67.80M	-167.71M	-133.40M

Danel Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 46540.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:DANE, the sentiment is Positive. The current price of 46540 is above the 20-day moving average (MA) of 45644.28, below the 50-day MA of 47711.37, and above the 200-day MA of 43778.66, indicating a neutral trend. The MACD of -297.89 indicates Negative momentum. The RSI at 51.69 is Neutral, neither overbought nor oversold. The STOCH value of 41.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:DANE.

Danel Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WLFD	74 Outperform	515.80M	15.36	―	―	―	―
RMLI	70 Outperform	4.78B	21.97	―	4.07%	6.10%	-9.48%
TTAM	67 Neutral	974.57M	16.79	―	1.78%	―	―
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
DANE	56 Neutral	2.75B	128.81	―	3.01%	5.94%	-52.48%
NVLG	56 Neutral	655.96M	32.67	―	3.10%	22.79%	―